Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
RGNXthis companyREGENXBIO Inc.	$8.12	-3.83×	7.23×	4.36×	-7.27×	-407.7%	88.1%	-94.6%	-113.8%	-188.7%	-42.1%	-17.0%	2.54×	-1.7×	-3.58×	2.38×	0.0%	5	-2.71	1	C-
FDMT4D Molecular Therapeutics, Inc.	$12.53	-3.1×	0.86×	5.1×	-2.99×	-174.0%	91.1%	-187.2%	-164.4%	-27.7%	-30.2%	-25.2%	0.04×	0.29×	0×	9.39×	0.0%	3	2.15	2	C
GNPXGenprex, Inc.	$2.09	-0.1×	0.21×	0×	0.4×	8100.2%	0.0%	0.0%	0.0%	-203.8%	-194.3%	-938.0%	0×	0.51×	-20.97×	3.84×	0.0%	2	-16.52	2	B-
LXEOLexeo Therapeutics, Inc. Common Stock	$3.18	-5.34×	2.16×	0×	-4.89×	-70.2%	0.0%	0.0%	0.0%	-40.5%	-42.9%	-18.6%	0.03×	0.56×	-530.37×	11.21×	0.0%	1	4.66	2	B-
MGTXMeiraGTx Holdings plc	$9.48	-5.6×	-110.38×	7.86×	-7.4×	-551.5%	94.0%	-130.2%	-140.3%	1971.4%	-70.9%	-7.8%	-15.31×	-0.25×	-8.69×	0.75×	0.0%	6	4.1	3	B
OCGNOcugen, Inc.	$0.99	-5.87×	-33.31×	91.83×	-6.97×	-121.9%	45.9%	-1425.7%	-1537.4%	557.7%	-278.6%	-14.1%	-2.72×	-0.24×	-12.13×	1.06×	0.0%	2	-6.82	2	C
Peer median	—	-5.34×	0.21×	5.1×	-4.89×	-121.9%	45.9%	-130.2%	-140.3%	-27.7%	-70.9%	-18.6%	0×	0.29×	-12.13×	3.84×	0.0%	2	2.15	2	—